HALOZYME THERAPEUTICS, INC. Tax Withholding Paid on Stock Awards
HALOZYME THERAPEUTICS, INC. (HALO) reported Tax Withholding Paid on Stock Awards of $1.61 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-05-11
- HALOZYME THERAPEUTICS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $1.61M, a 51.43% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-03-31 was $3.32M, a 579.14% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2024-03-31 was $489.00K, a 53.34% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2023-03-31 was $1.05M.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 3 month as first filed | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month as first filed |
|---|---|---|---|---|
| 2026-03-31 | $1.61M 10-Q · filed 2026-05-11 | |||
| 2025-03-31 | $3.32M 10-Q · filed 2026-05-11 | |||
| 2024-03-31 | $489.00K 10-Q · filed 2025-05-06 | |||
| 2023-03-31 | $1.05M 10-Q · filed 2024-05-07 | |||
| 2019-03-31 | $449.00K 10-Q · filed 2019-05-07 | |||
| 2014-06-30 | $79.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $932.00K 10-Q · filed 2014-08-11 | ||
| 2014-03-31 | $853.00K 10-Q · filed 2014-05-12 | |||
| 2013-06-30 | $65.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $374.00K 10-Q · filed 2014-08-11 | $373.79K 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $309.00K 10-Q · filed 2014-05-12 | $309.12K 10-Q · filed 2013-05-08 | ||
| 2012-06-30 | $347.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | $347.28K 10-Q · filed 2013-08-07 | ||
| 2012-03-31 | $0.00 10-Q · filed 2013-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |